Neoantigens are a series of immunogenic peptides produced by tumor-specific mutations, which can be used as biomarkers to distinguish cancer cells from normal cells. Since neoantigens are specifically expressed in tumor cells, their induction tolerance is low and they are safe targets when used in tumor immunotherapy.

The heterogeneity of tumor cells is the basis of tumor formation, so tumor is a kind of cellular disease. Compared with normal cells, tumor cells have abnormal structure, function and metabolism, and also have supernormal proliferation ability. In-depth study of the life cycle, invasion, apoptosis and metabolic mechanisms of tumor cells will help people to better understand the process of tumorigenesis. It also plays an important role in exploring tumor immunotherapy and immune escape, tumor targeted therapy, tumor drug resistance related research and tumor microenvironment. Tumor cell biology technology is the main method to study these biological problems, and it is also the main method used in basic research in recent years.

As an important marker in liquid biopsy technology, CTCs can reflect the more complete biological information of brain tumors. We offer clients a variety of methods based on CTCs detection in brain tumors. In addition, we also provide single-cell sequencing services for CTCs in brain tumors. We can identify individual CTCs or CTM oncogenes and oncogenes, and analyze brain tumor survival factors. This is very critical for real-time monitoring of brain tumor dynamics, assessing treatment efficacy, and personalizing treatment.

The construction of a tumour microenvironment (TME) to study tumour heterogeneity, tumour progression and subsequent metastasis, drug response and drug resistance has been a great challenge in cancer research. There are two effective research models, patient-derived xenografts (PDX) and patients derived organoids. Patient-derived organoids are miniature 3D tumor cell models that are cultured in the laboratory from primary tumors in patients with the disease. Patients derived organoids can encapsulate the tumor microenvironment including tumor cells and non-tumor host components, and are phenotypically and genetically similar to the tumor tissue from which they originate, highly mimicking the characteristics of the source tumor tissue, preserving tumor heterogeneity between individuals, and can be used for mechanistic studies and functional testing.

Exosomes are the smallest and most characteristic of extracellular vesicles and contain a variety of biological information, including proteins, lipids, DNA, mRNA, and microRNA. These biomolecules are involved in regulating various life activities such as signal transduction, proliferation, migration, and angiogenesis among tumor cells. Exosomes are not only a new biological marker assay, but also provide potential molecular therapeutic targets and are expected to be a carrier for anti-brain tumor drug delivery.

Neoantigen is a kind of tumor-specific antigen derived from non-synonymous mutations, which plays an important role in the killing of tumor by immune cells, and effective anti-tumor immunity is directly related to tumor neoantigen-specific T cells. Neoantigens are highly immunogenic and specific, not expressed in normal tissues, and bypass the central thymus without immune tolerance, making them ideal targets for anti-tumor immunotherapy. With the development of next-generation sequencing technology and the application of machine learning algorithms, it has become feasible to predict neoantigens, which can detect the differences between tumor cells and normal cells, and determine the best neoantigens to incorporate into tumor vaccines. The individualized nature of neoantigen immunotherapy typically requires 10-30 GMP-grade peptides (selected as neoantigens) to be manufactured for each patient. Peptide neoantigen therapy constitutes a significant paradigm-shift in GMP peptide manufactur

Tumor markers appear along with tumors and are usually increased in amounts of proteins, oncogenes, tumor suppressor genes and their related products in the form of antigens, enzymes, receptors, hormones or metabolites. It is produced and secreted by tumor cells, or is part of the released tumor cell structure. It exists only in tumor cells and is often released into serum or other body fluids, which can reflect the presence of tumors in the body to a certain extent. The detection and analysis of tumor biomarkers is the core of personalized and precise tumor therapy, which can determine the occurrence, development and prognosis of tumors. Complete and comprehensive detection is of great significance for elucidating the effect of anti-tumor drugs or drug resistance mechanisms, and screening characteristic populations.